Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...